Cell and Gene Therapy Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
Description
Cell and Gene Therapy Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
Cell therapy is the administration of living cells in patients for the treatment of a disease. The source of cell can be autologous or allogeneic, which can be derived from stem cells such as bone marrow. Stem cells therapy is used in bone marrow transplantation. Gene therapy is the introduction, removal, or change in the patient's genetic code for treatment of a disease. Moreover, it modifies the expression of an individual’s genes or repair abnormal genes. The therapy involves administration of nucleic acid (DNA/RNA) with carriers called as vectors.
Market Dynamics
Increasing prevalence of cancer diseases is a major factor driving the cell and gene therapy market growth. According to the World Cancer Research Funds and the American Institute for Cancer Research, in 2018, there were around 18 million cases of cancer, of which around 9.5 million were in men and around 8.5 million in women, globally. Moreover, introduction of innovative products and rich pipeline of cell and gene therapy is expected to boost the market growth. For instance, around 150 gene therapies are currently in the development stage. Gene replacement accounts for around two third of gene therapy pipeline. However, around 49% of gene therapies are under preclinical and discovery stages. During 2012-18, around 351 gene therapy deals were signed. For instance Gilead’s Kite Pharma received exclusive rights to Sangamo Therapeutics’ zinc finger nuclease gene editing technology, for $3.2bn.
Key features of the study:
This report provides in-depth analysis of the cell and gene therapy market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global cell and gene therapy market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Amgen, Biogen, BioMarin Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis, Pfizer, Regeneron Pharmaceuticals and Sanofi, Spark Therapeutics, Agilis Biotherapeutics, Angionetics AVROBIO, Freeline Therapeutics, Horama, MeiraGTx, Myonexus Therapeutics, Nightstar Therapeutics, Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., and MEDIPOST
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global cell and gene therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the cell and gene therapy market
Detailed Segmentation:
Global Cell and Gene Therapy Market, By Therapy Type:
Cell Therapy
Stem Cells
T Cells
Dendritic Cells
NK Cells
Tumor Cells
Gene Therapy
Global Cell and Gene Therapy Market, By Indication:
Cardiovascular Disease
Cancer
Genetic Disorder
Infectious Disease
Neurological Disorders
Others
Global Cell and Gene Therapy Market, By Scale of Operation:
In House
Outsourced
Global Cell and Gene Therapy Market, By Geography:
North America
By Therapy Type:
Cell Therapy
Stem Cells
T Cells
Dendritic Cells
NK Cells
Tumor Cells
Gene Therapy
By Indication:
Cardiovascular Disease
Cancer
Genetic Disorder
Infectious Disease
Neurological Disorders
Others
By Scale of Operation:
In House
Outsourced
By Country:
U.S.
Canada
Latin America
By Therapy Type:
Cell Therapy
Stem Cells
T Cells
Dendritic Cells
NK Cells
Tumor Cells
Gene Therapy
By Indication:
Cardiovascular Disease
Cancer
Genetic Disorder
Infectious Disease
Neurological Disorders
Others
By Scale of Operation:
In House
Outsourced
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Therapy Type:
Cell Therapy
Stem Cells
T Cells
Dendritic Cells
NK Cells
Tumor Cells
Gene Therapy
By Indication:
Cardiovascular Disease
Cancer
Genetic Disorder
Infectious Disease
Neurological Disorders
Others
By Scale of Operation:
In House
Outsourced
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Therapy Type:
Cell Therapy
Stem Cells
T Cells
Dendritic Cells
NK Cells
Tumor Cells
Gene Therapy
By Indication:
Cardiovascular Disease
Cancer
Genetic Disorder
Infectious Disease
Neurological Disorders
Others
By Scale of Operation:
In House
Outsourced
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Therapy Type:
Cell Therapy
Stem Cells
T Cells
Dendritic Cells
NK Cells
Tumor Cells
Gene Therapy
By Indication:
Cardiovascular Disease
Cancer
Genetic Disorder
Infectious Disease
Neurological Disorders
Others
By Scale of Operation:
In House
Outsourced
By Country:
GCC
Israel
Rest of Middle East
Africa
By Therapy Type:
Cell Therapy
Stem Cells
T Cells
Dendritic Cells
NK Cells
Tumor Cells
Gene Therapy
By Indication:
Cardiovascular Disease
Cancer
Genetic Disorder
Infectious Disease
Neurological Disorders
Others
By Scale of Operation:
In House
Outsourced
By Country:
South Africa
Central Africa
North Africa
Company Profiles
Amgen *
Company Overview
Product Portfolio
Financial Performance
Key Highlights
Market Strategies
Biogen
BioMarin Pharmaceuticals
Bristol-Myers Squibb Company
GlaxoSmithKline
Novartis
Pfizer
Regeneron Pharmaceuticals and Sanofi
Spark Therapeutics
Agilis Biotherapeutics
Angionetics AVROBIO
Freeline Therapeutics
Horama
MeiraGTx
Myonexus Therapeutics
Nightstar Therapeutics
Kolon TissueGene, Inc.
JCR Pharmaceuticals Co., Ltd.
MEDIPOST
“*” marked represents similar segmentation in other categories in the respective section.
Cell therapy is the administration of living cells in patients for the treatment of a disease. The source of cell can be autologous or allogeneic, which can be derived from stem cells such as bone marrow. Stem cells therapy is used in bone marrow transplantation. Gene therapy is the introduction, removal, or change in the patient's genetic code for treatment of a disease. Moreover, it modifies the expression of an individual’s genes or repair abnormal genes. The therapy involves administration of nucleic acid (DNA/RNA) with carriers called as vectors.
Market Dynamics
Increasing prevalence of cancer diseases is a major factor driving the cell and gene therapy market growth. According to the World Cancer Research Funds and the American Institute for Cancer Research, in 2018, there were around 18 million cases of cancer, of which around 9.5 million were in men and around 8.5 million in women, globally. Moreover, introduction of innovative products and rich pipeline of cell and gene therapy is expected to boost the market growth. For instance, around 150 gene therapies are currently in the development stage. Gene replacement accounts for around two third of gene therapy pipeline. However, around 49% of gene therapies are under preclinical and discovery stages. During 2012-18, around 351 gene therapy deals were signed. For instance Gilead’s Kite Pharma received exclusive rights to Sangamo Therapeutics’ zinc finger nuclease gene editing technology, for $3.2bn.
Key features of the study:
This report provides in-depth analysis of the cell and gene therapy market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global cell and gene therapy market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Amgen, Biogen, BioMarin Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis, Pfizer, Regeneron Pharmaceuticals and Sanofi, Spark Therapeutics, Agilis Biotherapeutics, Angionetics AVROBIO, Freeline Therapeutics, Horama, MeiraGTx, Myonexus Therapeutics, Nightstar Therapeutics, Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., and MEDIPOST
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global cell and gene therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the cell and gene therapy market
Detailed Segmentation:
Global Cell and Gene Therapy Market, By Therapy Type:
Cell Therapy
Stem Cells
T Cells
Dendritic Cells
NK Cells
Tumor Cells
Gene Therapy
Global Cell and Gene Therapy Market, By Indication:
Cardiovascular Disease
Cancer
Genetic Disorder
Infectious Disease
Neurological Disorders
Others
Global Cell and Gene Therapy Market, By Scale of Operation:
In House
Outsourced
Global Cell and Gene Therapy Market, By Geography:
North America
By Therapy Type:
Cell Therapy
Stem Cells
T Cells
Dendritic Cells
NK Cells
Tumor Cells
Gene Therapy
By Indication:
Cardiovascular Disease
Cancer
Genetic Disorder
Infectious Disease
Neurological Disorders
Others
By Scale of Operation:
In House
Outsourced
By Country:
U.S.
Canada
Latin America
By Therapy Type:
Cell Therapy
Stem Cells
T Cells
Dendritic Cells
NK Cells
Tumor Cells
Gene Therapy
By Indication:
Cardiovascular Disease
Cancer
Genetic Disorder
Infectious Disease
Neurological Disorders
Others
By Scale of Operation:
In House
Outsourced
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Therapy Type:
Cell Therapy
Stem Cells
T Cells
Dendritic Cells
NK Cells
Tumor Cells
Gene Therapy
By Indication:
Cardiovascular Disease
Cancer
Genetic Disorder
Infectious Disease
Neurological Disorders
Others
By Scale of Operation:
In House
Outsourced
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Therapy Type:
Cell Therapy
Stem Cells
T Cells
Dendritic Cells
NK Cells
Tumor Cells
Gene Therapy
By Indication:
Cardiovascular Disease
Cancer
Genetic Disorder
Infectious Disease
Neurological Disorders
Others
By Scale of Operation:
In House
Outsourced
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Therapy Type:
Cell Therapy
Stem Cells
T Cells
Dendritic Cells
NK Cells
Tumor Cells
Gene Therapy
By Indication:
Cardiovascular Disease
Cancer
Genetic Disorder
Infectious Disease
Neurological Disorders
Others
By Scale of Operation:
In House
Outsourced
By Country:
GCC
Israel
Rest of Middle East
Africa
By Therapy Type:
Cell Therapy
Stem Cells
T Cells
Dendritic Cells
NK Cells
Tumor Cells
Gene Therapy
By Indication:
Cardiovascular Disease
Cancer
Genetic Disorder
Infectious Disease
Neurological Disorders
Others
By Scale of Operation:
In House
Outsourced
By Country:
South Africa
Central Africa
North Africa
Company Profiles
Amgen *
Company Overview
Product Portfolio
Financial Performance
Key Highlights
Market Strategies
Biogen
BioMarin Pharmaceuticals
Bristol-Myers Squibb Company
GlaxoSmithKline
Novartis
Pfizer
Regeneron Pharmaceuticals and Sanofi
Spark Therapeutics
Agilis Biotherapeutics
Angionetics AVROBIO
Freeline Therapeutics
Horama
MeiraGTx
Myonexus Therapeutics
Nightstar Therapeutics
Kolon TissueGene, Inc.
JCR Pharmaceuticals Co., Ltd.
MEDIPOST
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
164 Pages
- 1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Therapy Type
- Market Snippet, By Indication
- Market Snippet, By Scale of Operation
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Diagnostic Algorithm
- Pipeline Analysis
- Reimbursement Scenario
- Epidemiology
- Pest Analysis
- 4. Global Cell and Gene Therapy Market, By Therapy Type, 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Stem Cells
- T Cells
- Dendritic Cells
- NK Cells
- Tumor Cells
- Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- 5. Global Cell and Gene Therapy Market, By Indication, 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Cardiovascular Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Genetic Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Infectious Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Neurological Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- 6. Global Cell and Gene Therapy Market, By Scale of Operation, 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- In-house
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Outsourced
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- 7. Global Cell and Gene Therapy Market, By Region, 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2028
- North America
- Market Size and Forecast, By Therapy Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Scale of Operation, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Therapy Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Scale of Operation, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Therapy Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Scale of Operation, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Therapy Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Scale of Operation, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Therapy Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Scale of Operation, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Therapy Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Scale of Operation, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- South Africa
- Central Africa
- North Africa
- 8. Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Amgen
- Company Overview
- Therapy Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Biogen
- Company Overview
- Therapy Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- BioMarin Pharmaceuticals
- Company Overview
- Therapy Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bristol-Myers Squibb Company
- Company Overview
- Therapy Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- GlaxoSmithKline
- Company Overview
- Therapy Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Novartis
- Company Overview
- Therapy Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Pfizer
- Company Overview
- Therapy Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Regeneron Pharmaceuticals and Sanofi
- Company Overview
- Therapy Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Spark Therapeutics
- Company Overview
- Therapy Type Portfolio
- Financial Overview
- Key Highlights
- Agilis Biotherapeutics
- Company Overview
- Therapy Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Angionetics AVROBIO
- Company Overview
- Therapy Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Freeline Therapeutics
- Company Overview
- Therapy Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Horama
- Company Overview
- Therapy Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- MeiraGTx
- Company Overview
- Therapy Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Myonexus Therapeutics
- Company Overview
- Therapy Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Nightstar Therapeutics
- Company Overview
- Therapy Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Kolon TissueGene, Inc.
- Company Overview
- Therapy Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- JCR Pharmaceuticals Co., Ltd.
- Company Overview
- Therapy Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- MEDIPOST
- Company Overview
- Therapy Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Analyst Views
- 9. Section
- References
- Research Methodology
- About us and Sales Contact
- *Browse 35 market data tables and 28 figures on "Cell and Gene Therapy Market - Global forecast to 2028”.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.